满￥6666，赠豪华版黑神话悟空
Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
药物研究 酶学 蛋白降解靶向嵌合体 囊泡 肿瘤
/
小分子阳性药
酶制剂 细胞凋亡 其他抑制剂/激动剂 E3配体砌块 帕金森与阿尔茨海默症 肿瘤发展和微环境演变
/
TNF-alpha
抗炎 CRBN配体 凋亡 E3泛素连接酶
/ Pomalidomide

泊马度胺 /Pomalidomide 98%

货号：A203253 同义名： CC-4047;3-amino Thalidomide Ambeed 开学季，买赠积分，赢豪礼

Pomalidomide是一种第三代免疫调节剂，通过与 E3 连接酶 cereblon 相互作用并诱导必需的 Ikaros 转录因子降解，作为分子胶作用。

Pomalidomide 化学结构 CAS号：19171-19-8
Pomalidomide 化学结构
CAS号：19171-19-8
Pomalidomide 3D分子结构
CAS号：19171-19-8
Pomalidomide 化学结构 CAS号：19171-19-8
Pomalidomide 3D分子结构 CAS号：19171-19-8
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Pomalidomide 纯度/质量文件 产品仅供科研

货号：A203253 标准纯度： 98%
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Cell,2024. Ambeed. [ A125712 ]
• Cancer Discov., 2024. Ambeed. [ A285925 ]
• JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]
• JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]
• EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]
更多 >
产品名称 TNF-α ↓ 其他靶点 纯度
Thalidomide ✔ E3 Ligase 98%
GSK2982772 ++

human RIP1, IC50: 16 nM

 		99%+
QNZ ++++

TNF-α, IC50: 7 nM

 		NF-κB 99%+
Lenalidomide +++

TNF-α, IC50: 13 nM

 		98%
Pomalidomide +++

TNF-α, IC50: 13 nM

 		98%
GSK481 ✔ 99%+
Apremilast ++

TNF-α, IC50: 77 nM

 		98%
Necrostatin-1 +

RIP1, EC50: 490 nM

 		99%+
N-Ac-Cys-OH ✔ 98%
Adalimumab ✔ 95%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Pomalidomide 生物活性

靶点

  • TNF-α

    TNF-α, IC50:13 nM

  • CRBN
描述 Cereblon, encoded by CRBN gene, is the substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Cereblon, or the E3 ligase complex mediated normal degradation of key regulatory proteins is required for multiple biological processes, such as normal limb outgrowth. It is well reported that binding of thalidomide-related drugs, such as Lenalidomide, changes the substrate specificity of the E3 ligase complex, leading to decreased degradation of MEIS2 and other target proteins and increased degradation of MYC, IRF4, IKZF1 and IKZF3[5]. Pomalidomide is an analogue of thalidomide. The cellular target of pomalidomide is cereblon. In a fluorescence thermal melt assay utilizing recombinant CRBN (cereblon), it was revealed that pomalidomide bound to cereblon[6]. Pomalidomide increased HbF production in human erythroid cells at the concentration of 1 μM. After incubation for 6 days, pomalidomide induced 2-fold upregulation of γ-globin mRNA levels while decreased β-globin levels 2-fold, also at the concentration of 1 μM[7]. According to another report, pomalidomide was used at the concentrations between 1 nM and 10 μM in both CD4+ and CD8+ cells, pomalidomide significantly elevated IL-2, IL-5, IL-10, and IFN-γSchafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP, Wolbring G, Govinda S, Corral LG, Payvandi F, Muller GW, Stirling DI. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003 Jun;305(3):1222-32. doi: 10.1124/jpet.102.048496. Epub 2003 Mar 20. PMID: 12649301.|. 8 doses of pomalidomide i.p. administrated at the dose of 0.5 mg/kg among a period of 19 days significantly enhanced the antitumor activity of rituximab in a disseminated lymphoma-bearing SCID mice xenograft model established by i.v. injection of Raji cells. The median survival time of animals treated with pomalidomide and rituximab was 74 days compared to 38 days of those treated with rituximab monotherapy, while pomalidomide was not effective as a single agent[8].

Pomalidomide 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
APK-1 39-1250 nM Growth Inhibition Assay 5 d IC50=226 nM, inhibits cell viability dose dependently 26119939
BC-1 39-1250 nM Growth Inhibition Assay 5 d IC50=744 nM, inhibits cell viability dose dependently 26119939
BC-3 39-1250 nM Growth Inhibition Assay 5 d IC50=107 nM, inhibits cell IC50=107 nM, viability dose dependently 26119939
BCBL-1 39-1250 nM Growth Inhibition Assay 5 d IC50=74 nM, inhibits cell viability dose dependently 26119939

Pomalidomide 动物研究

Dose Mice: 50 mg/kg[3] (p.o.); 7 mg/kg[4] (i.p.)
Administration p.o., i.p.
Pharmacokinetics
Animal Rats[3]
Dose 5 mg/kg (i.v.)
50 mg/kg (p.o.)
Administration i.v.
p.o.
AUCinf 7016 ± 1551 ng·h/ml (i.v.)
Vd 1.75 ± 0.2 L/kg (i.v.)
T1/2 2.44 ± 0.8 h (i.v.)
Brain: blood 0.39 ± 0.03
Tmax 4.1 ± 1.5 h (p.o.)
CL 12.3 ± 2.6 ml/min/kg (i.v.)
Cmax 430.0 ± 63 ng/ml (p.o.)
AUC0-10 2700 ± 740 ng·h/ml (p.o.)

Pomalidomide 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01745640 Multiple Myeloma Phase 2 Completed - France ... 展开 >> CHRU-Hôpital Sud Amiens Amiens, France, 80054 Chru Caen Caen, France, 14033 CHU DIJON, Hôpital d'Enfants Dijon, France, 21000 CHRU, Hôpital A.Michallon Grenoble, France, 38043 Centre hospitalier départemental La Roche sur Yon La Roche sur Yon, France, 85025 Chru Lille Lille, France, 59037 Institut Paoli Calmette, Marseille, France, 13273 CHRU, Hôtel Dieu Nantes, France, 44035 Hôpital Saint-Louis Paris, France, 75475 CHU - Hôpital St Antoine, Paris, France, 75571 Hôpital Haut-Leveque PESSAC cedex, France, 33604 Centre Hospitalier Lyon Sud -1 Pierre Benite, France, 69495 Centre Hospitalier Lyon Sud -2 Pierre Benite, France, 69495 CHRU POITIERS-Hôpital Jean Bernard Poitiers, France, 86021 Hôpital Robert Debré, CHU Reims Reims, France, 51092 CHRU RENNES 2, Hôpital Pontchaillou Rennes, France, 35033 CHRU RENNES 1, Hôpital Sud Rennes, France, 35056 CHRU, Hôpital Purpan Toulouse, France, 31059 CHRU- Hôpital Bretonneau Tours, France, 37044 CHRU, Hôpitaux de Brabois Vandoeuvre, France, 54511 收起 <<
NCT03227432 Multiple Myeloma Phase 2 Withdrawn(Withdrawn before enr... 展开 >>ollment due to issues around the FDA hold on PD-1/PD-L1 drugs in combination with IMIDs.) 收起 << December 31, 2024 United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT02654132 Multiple Myeloma Phase 2 Active, not recruiting April 22, 2019 -

Pomalidomide 参考文献

[1]Li Z, Qiu Y, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013 Aug 5;8(8):e71754.

[2]Ocio EM, Fernández-Lázaro D, et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia. 2015 Mar;29(3):705-14.

[3]Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG Jr. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014 Jan 17;343(6168):305-9. doi: 10.1126/science.1244917. Epub 2013 Nov 29. PMID: 24292623; PMCID: PMC4070318.

[4]Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35. doi: 10.1038/leu.2012.119. Epub 2012 May 3. Erratum in: Leukemia. 2012 Nov;26(11):2445. PMID: 22552008; PMCID: PMC3496085.

[5]Moutouh-de Parseval LA, Verhelle D, Glezer E, Jensen-Pergakes K, Ferguson GD, Corral LG, Morris CL, Muller G, Brady H, Chan K. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest. 2008 Jan;118(1):248-58. doi: 10.1172/JCI32322. PMID: 18064299; PMCID: PMC2117764.

[6]Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11(16):5984-92. doi: 10.1158/1078-0432.CCR-05-0577. PMID: 16115943.

Pomalidomide 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.66mL

0.73mL

0.37mL

18.30mL

3.66mL

1.83mL

36.60mL

7.32mL

3.66mL

Pomalidomide 技术信息

CAS号19171-19-8
分子式C13H11N3O4
分子量 273.24
别名 CC-4047;3-amino Thalidomide;Pomalidomide. Brand name: Pomalyst.
运输蓝冰
存储条件

粉末 Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度

DMSO: 50 mg/mL(182.99 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

2% DMSO+30% PEG 300+2% Tween 80+water 3 mg/mL

Tags: Pomalidomide | CC-4047;3-amino Thalidomide;Pomalidomide.| Anti-inflammation | E3 Ubiquitin Ligase | Apoptosis | TNF-alpha | CRBN Ligand | AmBeed-信号通路专用抑制剂 | Pomalidomide 纯度/质量文件 | Pomalidomide 亚型比较 | Pomalidomide 生物活性 | Pomalidomide 细胞研究 | Pomalidomide 动物研究 | Pomalidomide 临床数据 | Pomalidomide 参考文献 | Pomalidomide 实验方案 | Pomalidomide 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z